---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-014751"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:58:14.432089+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CytomX Q2 2022 revenue $18M; cash $228M; restructuring extends runway to 2025

## Summary
- Cash and investments $228M at June 30, 2022, down from $305M at Dec 31, 2021.
- Total revenue $18M for Q2 2022, up from $16M in Q2 2021; R&D expense $31M (+$5M YoY).
- Company restructuring announced July 2022 aims to extend cash runway into 2025.
- IND filings planned for CX-801 (IFN alpha-2b) and CX-2051 (EpCAM ADC) in H2 2023.
- CX-2029 data update for squamous NSCLC expected Q4 2022; praluzatamab ravtansine also updating Q4 2022.

## SEC filing metadata
- accession: 0000950170-22-014751
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017022014751/0000950170-22-014751-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017022014751/ctmx-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-014751
- JSON: https://secwatch.observer/filing/0000950170-22-014751.json
- Plain text: https://secwatch.observer/filing/0000950170-22-014751.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.